<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23787" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Isoniazid Toxicity</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Badrinath</surname>
            <given-names>Madhuri</given-names>
          </name>
          <aff>SUNY Upstate Medical university</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chen</surname>
            <given-names>Philip</given-names>
          </name>
          <aff>University of Texas Health San Antonio</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>John</surname>
            <given-names>Savio</given-names>
          </name>
          <aff>SUNY Upstate Medical University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Madhuri Badrinath declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Philip Chen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Savio John declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23787.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Isoniazid (INH) is a potent bactericidal antibiotic&#x000a0;prescribed for tuberculosis (TB). Treatment with INH therapy has a risk of toxicity, which&#x000a0;is acute or chronic, leading to long-term liver damage if not appropriately treated. Acute toxicity manifests as neurological symptoms, often in the form of seizures refractory to benzodiazepines. Chronic toxicity usually presents as hepatotoxicity and peripheral neuropathy.&#x000a0;The&#x000a0;toxicity may easily present in the full spectrum of medical settings, though less likely in emergency departments, if pyridoxine is prescribed with INH from therapy initiation.&#x000a0;With increasing INH prescriptions for TB, cases of INH toxicity may rise due to dosage errors. Management includes discontinuing INH, administering pyridoxine for acute toxicity, considering liver support therapies if hepatic damage occurs, and occasionally resorting to liver transplants.</p>
        <p>Throughout this activity, participants explore the spectrum of INH toxicity presentations, learning to recognize key features and differentiate them from other drug toxicities. Emphasis is placed on early intervention strategies, including administering pyridoxine for acute toxicity and appropriate management of chronic hepatotoxicity. Moreover, this course underscores the importance of an interprofessional approach in managing INH toxicity, highlighting the collaborative efforts of clinicians across specialties. By participating in this course, clinicians enhance their competence in recognizing, diagnosing, and managing INH toxicity, ultimately improving patient outcomes and ensuring safe prescribing practices in TB treatment.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Determine&#x000a0;the pathophysiology of isoniazid (INH) toxicity, including both acute and chronic presentations.</p></list-item><list-item><p>Interpret&#x000a0;the presentation of&#x000a0;isonizaid toxicity to determine the next best steps appropriately.</p></list-item><list-item><p>Implement the treatment options for isoniazid toxicity, considering medication interactions and exposure duration.</p></list-item><list-item><p>Coordinate strategies among&#x000a0;interprofessional team members to identify patients affected by&#x000a0;isoniazid&#x000a0;toxicity and treat the condition rapidly.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23787&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23787">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23787.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Isoniazid (INH) is a potent bactericidal tuberculosis (TB) antibiotic. Treatment with INH therapy has a risk of toxicity, which is acute or chronic. Acute toxicity manifests as neurological symptoms, specifically seizures. Consumption of as little as 2 g of INH can predispose a patient to acute toxicity. Patients with certain risk factors and prolonged use can develop chronic toxicity, presenting as hepatotoxicity and peripheral neuropathy.&#x000a0;</p>
        <p>Two known syndromes of hepatotoxicity are recognized:&#x000a0;</p>
        <list list-type="order">
          <list-item>
            <p>Mild type manifesting as transient and asymptomatic elevation in serum aminotransferase levels</p>
          </list-item>
          <list-item>
            <p>Severe acute hepatitis that is fatal&#x000a0;<xref ref-type="bibr" rid="article-23787.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>Peripheral neuropathy is secondary to vitamin B6 (pyridoxine) deficiency, though the prevalence is relatively low.</p>
      </sec>
      <sec id="article-23787.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Isoniazid is a potent antimycobacterial agent that inhibits TB cell wall synthesis and is used in therapeutic and prophylactic regimens. Introduced in 1954, INH has contributed to the treatment of TB, resulting in a significant decline in TB-related morbidity and mortality. The recommended dose of INH in adults is 300 mg (5 mg/kg) daily to 900 mg (15 mg/kg) once or twice weekly. Due to the rapid development of microorganism resistance, treatment regimens include other antibacterial agents. Most of the regimens have INH alone or with other agents, including rifampin, pyrazinamide, streptomycin, or ethambutol. Common side effects include gastrointestinal upset, fever, and rash. High doses of INH can cause peripheral neuropathy, preventable with concurrent administration of pyridoxine (vitamin B6).&#x000a0;</p>
        <p>Hepatotoxicity development increases with other contributing risk factors such as increased age, alcohol consumption, concurrent use of medications that induce cytochrome P oxidative enzymes, prior or concurrent liver disease like viral hepatitis, previous INH intolerance, female sex, injection drug use, and genetic causes like slow acetylation status.<xref ref-type="bibr" rid="article-23787.r2">[2]</xref><xref ref-type="bibr" rid="article-23787.r3">[3]</xref></p>
      </sec>
      <sec id="article-23787.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Acute toxicity is rarely reported in the United States. According to the report from the American Association of Poison Control Centers based on the National Poison Data System, only 54 cases of INH toxicity were reported in 2020, with the majority being unintentional, such as in the case of exploratory ingestions in children.<xref ref-type="bibr" rid="article-23787.r4">[4]</xref>&#x000a0;Transient asymptomatic liver enzyme elevation due to INH is seen in 15% to 20% of recipients. INH-induced, clinically apparent, acute liver injury with jaundice is seen in 0.5% to 1% of recipients, and the risk of fatal hepatitis is about 0.05% to 1%. While the occurrence of mild hepatotoxicity is not related to acetylation status, the occurrence of acute hepatitis can depend on it.<xref ref-type="bibr" rid="article-23787.r5">[5]</xref>&#x000a0;The incidence of peripheral neuropathy is 1.1% in the general population and around 6.5% in older patients.</p>
      </sec>
      <sec id="article-23787.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>A functional pyridoxine deficiency causes INH toxicity. This occurs via 2 different mechanisms. In normal physiology, pyridoxine is metabolized to an active form, pyridoxal-5'-phosphate, an important cofactor in several biotransformation reactions. INH metabolites can inhibit the enzyme pyridoxine phosphokinase, which converts pyridoxine to its active form. INH also directly combines with pyridoxal phosphate, forming an inactive hydrazone. This complex is renally excreted.<xref ref-type="bibr" rid="article-23787.r6">[6]</xref>&#x000a0;Increasing doses of INH also lead to increased urinary excretion of pyridoxine. This functional depletion is similar to that which occurs in gyromitrin mushroom poisoning and poisoning from rocket fuel (hydrazine).</p>
        <p>Acute toxicity manifests due to the depletion of gamma-aminobutyric acid (GABA) neurotransmitters. Functional depletion of pyridoxine leads to the inhibition of glutamic acid decarboxylase, which converts glutamate to GABA.<xref ref-type="bibr" rid="article-23787.r7">[7]</xref>&#x000a0;Hepatic injury is thought to occur through 2 mechanisms. The first is an immunologic process. The more common mechanism involves INH metabolites hydrazine, acetylhydrazine, and free radicals that are involved in the pathogenesis of INH-induced hepatitis. INH is metabolized via the N-acetyltransferase 2 gene (NAT2) to form the inactive N1-acetyl-N2-isonicotinohydrazide (AcINH), which is then hydrolyzed to form monoacetylhydrazine (AcHZ) and isonicotinic acid, INA. These metabolites are further acetylated to non-toxic metabolites and excreted in the urine. As NAT2 is the primary enzyme involved in the metabolism of INH, its deficiency can cause INH-related hepatotoxicity. This is particularly seen in slow acetylators due to the higher concentration of AcHZ.</p>
        <p>The incidence of toxic hepatitis increases when INH is used with rifampin, pyrazinamide, or barbiturates, as these medications are inducers of the cytochrome P (CYP) enzyme system, resulting in increased production of toxic INH metabolites.<xref ref-type="bibr" rid="article-23787.r8">[8]</xref><xref ref-type="bibr" rid="article-23787.r9">[9]</xref><xref ref-type="bibr" rid="article-23787.r10">[10]</xref>&#x000a0;CYP2E1 likely plays a vital role.<xref ref-type="bibr" rid="article-23787.r3">[3]</xref><xref ref-type="bibr" rid="article-23787.r11">[11]</xref>&#x000a0;INH causes peripheral neuropathy through the depletion of pyridoxine via the mechanisms mentioned above. Risk factors for the development of neuropathy include malnutrition, alcohol use, uremia or renal failure, and diabetes. Slow acetylators are also at higher risk. INH is also associated with optic neuritis, particularly in patients who are also metabolizing ethambutol and etanercept.<xref ref-type="bibr" rid="article-23787.r12">[12]</xref><xref ref-type="bibr" rid="article-23787.r13">[13]</xref><xref ref-type="bibr" rid="article-23787.r14">[14]</xref></p>
      </sec>
      <sec id="article-23787.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Liver biopsy of INH hepatotoxicity reveals morphologic changes similar to viral hepatitis, such as bridging necrosis, increased numbers of eosinophils, and prominence of cholestasis.<xref ref-type="bibr" rid="article-23787.r15">[15]</xref><xref ref-type="bibr" rid="article-23787.r16">[16]</xref></p>
      </sec>
      <sec id="article-23787.s7" sec-type="Toxicokinetics">
        <title>Toxicokinetics</title>
        <p>Therapeutic doses of INH vary between 300 mg daily to 900 mg&#x000a0;2 to&#x000a0;3 times a week. When an oral dose of 300 mg is taken, it is rapidly absorbed with peak serum concentrations occurring within 2 hours, ranging between 3 to 5 &#x003bc;g/mL.<xref ref-type="bibr" rid="article-23787.r17">[17]</xref><xref ref-type="bibr" rid="article-23787.r18">[18]</xref>&#x000a0;Delayed absorption leading to peak serum concentrations at 6 hours post-ingestion is also possible.<xref ref-type="bibr" rid="article-23787.r19">[19]</xref></p>
        <p>INH is metabolized primarily via acrylamide NAT2 to acetyl isoniazid, which is renally excreted and metabolized further to hydrazine or acetyl hydrazine. These metabolites are further metabolized into reactive metabolites, leading to increased oxidative stress in the liver and hepatic damage. Between 75% to 95% of these metabolites are renally excreted within 24 hours of ingestion.</p>
      </sec>
      <sec id="article-23787.s8" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Acute toxicity presents as altered mental status, seizures, and sometimes status epilepticus.<xref ref-type="bibr" rid="article-23787.r20">[20]</xref>&#x000a0;Long-term complications include anoxic encephalopathy and dementia. The onset of INH-induced hepatotoxicity is insidious, ranging from 2 weeks to 6 months. Toxicity usually affects adults around 35 years, with the highest frequency among those over 50 years. Other risk factors include chronic supratherapeutic dosing and co-administration of other anti-tuberculous drugs, such as rifampin and malnutrition. The symptoms are similar to viral hepatitis, with prodromal symptoms of nausea, anorexia, fatigue, abdominal discomfort, right upper quadrant pain, generalized flu-like symptoms, dark urine, and jaundice.</p>
        <p>Neuropathy symptoms are usually sensory and include numbness, tingling, and a burning sensation in all the extremities; they present in a stocking-glove distribution and progress proximally.<xref ref-type="bibr" rid="article-23787.r21">[21]</xref>&#x000a0;Central features like ataxia and nystagmus are rarely seen. Patients with optic neuritis will have decreased visual acuity, eye pain, and dyschromatopsia. Patients can also have central scotoma and bitemporal hemianopsia on visual field testing.<xref ref-type="bibr" rid="article-23787.r22">[22]</xref></p>
      </sec>
      <sec id="article-23787.s9" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Lab evaluation should include complete blood counts, a basic metabolic panel, a hepatic function panel, a creatinine kinase level, a lactate level, and arterial or venous blood gas. If available, INH serum concentrations can be considered, but this testing is not readily available, and care should not be delayed.</p>
        <p>Acute toxicity manifests as seizures, metabolic acidosis, and coma. The metabolic acidosis is associated with elevated lactate, likely secondary to muscle contraction from seizure activity.<xref ref-type="bibr" rid="article-23787.r23">[23]</xref>&#x000a0;Acute toxicity is associated with INH serum concentrations greater than 10 &#x003bc;g/mL at 1 hour, 3.2 &#x003bc;g/mL at 2 hours, and 0.2 &#x003bc;g/mL at 6 hours.<xref ref-type="bibr" rid="article-23787.r24">[24]</xref>&#x000a0;Management should not be delayed waiting for serum INH concentrations. In chronic toxicity, the pattern of elevation of liver enzymes is consistent with a hepatocellular injury with marked alanine aminotransferase and aspartate aminotransferase elevations (greater than 10 times the upper limit of normal) and minimal alkaline phosphatase elevations. The injury is mostly self-limited except for 10% of the cases where it can progress to acute liver failure with clinical manifestations of coagulopathy, ascites, edema, and encephalopathy.<xref ref-type="bibr" rid="article-23787.r25">[25]</xref>&#x000a0;</p>
        <p>INH therapy can induce the production of antinuclear antibodies (ANA). These can be present during the acute hepatic injury phase but usually in very low titers. As ANA can also be positive in autoimmune hepatitis, the absence of arthralgia and hyperglobulinemia can help differentiate it from INH-induced hepatotoxicity. Recently, antibodies to INH have been detected in INH recipients, but their presence is not fully linked to liver injury.</p>
      </sec>
      <sec id="article-23787.s10" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Acute toxicity is approached by strict airway management, activated charcoal if the patient presents early, seizure management with the use of benzodiazepines, and pyridoxine administration (this helps with the rapid restoration of GABA stores).<xref ref-type="bibr" rid="article-23787.r26">[26]</xref>&#x000a0;If the amount of INH ingested is known, pyridoxine should be given at a gram-for-gram equivalent dose. If the amount of INH is unknown, a 70 mg/kg dose up to a maximum of 5 g is recommended. A second dose can be given if a patient continues to have seizures. Rapid resolution of seizure and coma is expected with pyridoxine administration.<xref ref-type="bibr" rid="article-23787.r27">[27]</xref>&#x000a0;In patients presenting with renal failure, massive ingestions, or insufficient pyridoxine to treat a patient, extracorporeal removal is considered.<xref ref-type="bibr" rid="article-23787.r28">[28]</xref></p>
        <p>Elevated serum aminotransferase levels develop during the first few weeks of therapy and are termed mild INH hepatotoxicity. In most cases, such toxicity is self-limiting, and the adaptive response allows the continuation as long as patients remain asymptomatic without a progressive elevation in aminotransferase levels. However, INH should be immediately discontinued if hepatitis-related symptoms or progressive elevation in aminotransferase levels are present. The onset of any symptoms of hepatitis, such as anorexia, nausea, jaundice, and fatigue in a patient with abnormal liver biochemical tests, should prompt cessation of INH.</p>
        <p>The exact level of aminotransferases at which INH should be discontinued is unclear; the general recommendation is that if the total bilirubin is greater than 3 mg/dL and liver enzymes are over 5 times the upper limit of normal, INH (including other anti-TB medications) should be discontinued. If the bilirubin is less than 3 mg/dL and liver enzymes are less than 5 times the upper limit of normal, therapy can be continued, but liver enzymes should be checked in 3 days.</p>
        <p>If liver enzymes continue to worsen or patients develop symptoms of hepatitis, therapy should be discontinued, or close monitoring is recommended.<xref ref-type="bibr" rid="article-23787.r29">[29]</xref>&#x000a0;When the liver enzymes return to baseline (or less than twice normal), the potential hepatotoxic drugs can be restarted one at a time with careful monitoring. Rechallenge with INH may be done cautiously with serial monitoring of liver biochemical tests in patients with a strong indication for therapy and who have not had severe hepatoxicity.</p>
        <p>Many public health programs require INH prevention after a positive tuberculin skin test or a blood test for diagnosing TB infection, including monthly liver enzyme monitoring. However, limited evidence of benefit exists for such practice. Monitoring liver biochemical tests on therapy is generally recommended in patients with chronic liver disease or in those who are 50 years or older, as these individuals are at a higher risk for developing hepatotoxicity.<xref ref-type="bibr" rid="article-23787.r3">[3]</xref>&#x000a0;Though no specific therapies are evident for INH-induced liver damage, results from some studies have shown a mortality benefit in using corticosteroids and N-acetylcysteine early in the course of liver injury. In rare instances, the hepatotoxicity from INH is very severe, prompting the need for an emergency liver transplant.<xref ref-type="bibr" rid="article-23787.r30">[30]</xref>&#x000a0;Peripheral neuropathy can be prevented and treated by prescribing pyridoxine daily with INH.</p>
      </sec>
      <sec id="article-23787.s11" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Seizures and status epilepticus mainly characterize the presentation of acute INH toxicity. The differential is broad and includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Undiagnosed seizure disorder</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Metabolic disorder</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Intracranial hemorrhage</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Traumatic brain injury</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Ethanol withdrawal</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sedative or hypnotic withdrawal (eg, benzodiazepines, baclofen, barbiturates)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sympathomimetic toxicity</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hydrazine (eg, rocket fuel) toxicity</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Gyromitrin mushroom toxicity</p>
          </list-item>
        </list>
        <p>The main differential diagnoses of chronic INH toxicity include the differentials for jaundice and peripheral neuropathy.</p>
        <p>
<bold>Jaundice</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hemolytic jaundice</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Obstructive jaundice</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Other hepatotoxic drug toxicity: non-steroidal anti-inflammatory drugs, anti-virals for human immunodeficiency virus infection, statins</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Viral hepatitis</p>
          </list-item>
        </list>
        <p>
<bold>Peripheral Neuropathy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Alcoholic neuropathy</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Diabetic neuropathy</p>
          </list-item>
        </list>
        <p>
<bold>Optic Neuritis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Ethambutol toxicity</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Autoimmune disease (eg, lupus)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Multiple sclerosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Infectious</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23787.s12" sec-type="Toxicity and Adverse Effect Management">
        <title>Toxicity and Adverse Effect Management</title>
        <p>Isoniazid&#x000a0;has multiple drug-drug interactions that can either increase the risk of toxicity from INH or increase toxicity from other drugs. Many of these interactions arise from CYP450 enzyme inhibition, resulting in increased concentrations of respective substrates. These include CYP1A2, CYP2C9/CYP2C19, and CYP3A4.<xref ref-type="bibr" rid="article-23787.r31">[31]</xref><xref ref-type="bibr" rid="article-23787.r32">[32]</xref><xref ref-type="bibr" rid="article-23787.r33">[33]</xref>&#x000a0;A complex relationship with CYP2E1 is evident, with an initial inhibitory effect followed by activity induction. INH also possesses weak monoamine oxidase inhibitory activity.<xref ref-type="bibr" rid="article-23787.r34">[34]</xref><xref ref-type="bibr" rid="article-23787.r35">[35]</xref></p>
        <p>Described interactions include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Increased risk of hepatic necrosis due to rifampin, pyrazinamide, and ethanol</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Increased INR in the setting of warfarin use (CYP2C9/CYP2C19)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Unknown effects after interaction&#x000a0;with acetaminophen</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Increased&#x000a0;serum concentration of phenytoin (CYP2C9/CYP2C19), carbamazepine (CYP3A4), and theophylline (CYP1A2)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Increased serum INH after ingestion of food, antacids, and lactose</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Tyramine reaction following consumption of red wine or soft cheeses</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Worsened scombroid toxicity&#x000a0;<xref ref-type="bibr" rid="article-23787.r36">[36]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23787.s13" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis for INH toxicity is generally positive. In acute toxicity, rapid treatment with pyridoxine leads to the resolution of seizures, coma, and metabolic acidosis.<xref ref-type="bibr" rid="article-23787.r37">[37]</xref> In the setting of chronic toxicity, patients have complete recovery from peripheral neuropathy, optic neuritis, and other CNS toxicity&#x000a0;when pyridoxine is supplemented. In some patients, residual sensory neuropathy may persist.<xref ref-type="bibr" rid="article-23787.r38">[38]</xref><xref ref-type="bibr" rid="article-23787.r39">[39]</xref></p>
      </sec>
      <sec id="article-23787.s14" sec-type="Complications">
        <title>Complications</title>
        <p>Potential complications of INH toxicity include hepatic failure, coma, peripheral neuropathy, optic neuritis, encephalopathy, and death.</p>
      </sec>
      <sec id="article-23787.s15" sec-type="Consultations">
        <title>Consultations</title>
        <p>If concern for acute&#x000a0;INH toxicity is present, pyridoxine should be administered as soon as possible. Consultation with a medical toxicologist or&#x000a0;the regional poison control center should be obtained to help manage the patient's condition.</p>
      </sec>
      <sec id="article-23787.s16" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>The patient should be instructed on the proper dosing of INH. Instructions should be clear concerning the dose and frequency to avoid accidental overdose, especially in children.</p>
      </sec>
      <sec id="article-23787.s17" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>With rising rates of TB, the prescription of&#x000a0;INH has increased. Sometimes,&#x000a0;INH toxicity occurs because of multiple or inadvertent dosing.&#x000a0;INH toxicity is usually managed by an interprofessional team that consists of an emergency clinician, a nurse practitioner, a medical toxicologist, a certified specialist in poison information at a poison control center, a neurologist, and an internist.</p>
        <p>In all cases of&#x000a0;INH toxicity, the offending agent must first be discontinued. The treatment is pyridoxine for acute toxicity. If evidence of liver damage is seen, small case studies suggest the use of N-acetyl cysteine and corticosteroids. In rare cases, a liver transplant may be required. Today, peripheral neuropathy is rarely seen because most patients are prescribed pyridoxine at the initiation of&#x000a0;INH therapy.<xref ref-type="bibr" rid="article-23787.r40">[40]</xref><xref ref-type="bibr" rid="article-23787.r41">[41]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-23787.s18">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23787&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23787">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/medications/isoniazid-toxicity/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23787">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23787/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23787">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23787.s19">
        <title>References</title>
        <ref id="article-23787.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewinsohn</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Leonard</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>LoBue</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Cohn</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Daley</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Desmond</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Keane</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lewinsohn</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Loeffler</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Mazurek</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Pai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Richeldi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Salfinger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shinnick</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Sterling</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Warshauer</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children.</article-title>
            <source>Clin Infect Dis</source>
            <year>2017</year>
            <month>Jan</month>
            <day>15</day>
            <volume>64</volume>
            <issue>2</issue>
            <fpage>e1</fpage>
            <page-range>e1-e33</page-range>
            <pub-id pub-id-type="pmid">27932390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saukkonen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Cohn</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Jasmer</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Schenker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jereb</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Nolan</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Peloquin</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Gordin</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Nunes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Strader</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Bernardo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Venkataramanan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sterling</surname>
                <given-names>TR</given-names>
              </name>
              <collab>ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee</collab>
            </person-group>
            <article-title>An official ATS statement: hepatotoxicity of antituberculosis therapy.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2006</year>
            <month>Oct</month>
            <day>15</day>
            <volume>174</volume>
            <issue>8</issue>
            <fpage>935</fpage>
            <page-range>935-52</page-range>
            <pub-id pub-id-type="pmid">17021358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hassan</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Yousef</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Luyong</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhenzhou</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Hepatotoxicity mechanisms of isoniazid: A mini-review.</article-title>
            <source>J Appl Toxicol</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>35</volume>
            <issue>12</issue>
            <fpage>1427</fpage>
            <page-range>1427-32</page-range>
            <pub-id pub-id-type="pmid">26095833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gummin</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Mowry</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Beuhler</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Spyker</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Bronstein</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Rivers</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>NPT</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>2020 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 38th Annual Report.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>59</volume>
            <issue>12</issue>
            <fpage>1282</fpage>
            <page-range>1282-1501</page-range>
            <pub-id pub-id-type="pmid">34890263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayashi</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Chalasani</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Stolz</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Talwalkar</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Davern</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Kleiner</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hoofnagle</surname>
                <given-names>JH</given-names>
              </name>
              <collab>US Drug-Induced Liver Injury Network Investigators</collab>
            </person-group>
            <article-title>Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>13</volume>
            <issue>9</issue>
            <fpage>1676</fpage>
            <page-range>1676-82.e1</page-range>
            <pub-id pub-id-type="pmid">25724701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wason</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lacouture</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Lovejoy</surname>
                <given-names>FH</given-names>
              </name>
            </person-group>
            <article-title>Single high-dose pyridoxine treatment for isoniazid overdose.</article-title>
            <source>JAMA</source>
            <year>1981</year>
            <month>Sep</month>
            <day>04</day>
            <volume>246</volume>
            <issue>10</issue>
            <fpage>1102</fpage>
            <page-range>1102-4</page-range>
            <pub-id pub-id-type="pmid">7265398</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Citak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kaya</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>U&#x000e7;sel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Karab&#x000f6;c&#x000fc;o&#x0011f;lu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Uzel</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Acute isoniazid neurotoxicity in childhood.</article-title>
            <source>Turk J Pediatr</source>
            <year>2002</year>
            <season>Jan-Mar</season>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>54</fpage>
            <page-range>54-7</page-range>
            <pub-id pub-id-type="pmid">11858381</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weber</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Hein</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of isoniazid.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1979</year>
            <season>Nov-Dec</season>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>401</fpage>
            <page-range>401-22</page-range>
            <pub-id pub-id-type="pmid">391461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>Amarapurkar</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sasi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Joshi</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Baijal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ramegowda</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Amarapurkar</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Joshi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wangikar</surname>
                <given-names>PP</given-names>
              </name>
            </person-group>
            <article-title>Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India.</article-title>
            <source>J Gastroenterol Hepatol</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>28</volume>
            <issue>8</issue>
            <fpage>1368</fpage>
            <page-range>1368-74</page-range>
            <pub-id pub-id-type="pmid">23875638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Constantinescu</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Buysschaert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Haufroid</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Broly</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jadoul</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morelle</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Chronic dialysis, NAT2 polymorphisms, and the risk of isoniazid-induced encephalopathy - case report and literature review.</article-title>
            <source>BMC Nephrol</source>
            <year>2017</year>
            <month>Sep</month>
            <day>04</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>282</fpage>
            <pub-id pub-id-type="pmid">28870161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jaramillo-Valverde</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Levano</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Tarazona</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Capristano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zegarra-Chapo&#x000f1;an</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sanchez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yufra-Picardo</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Tarazona-Santos</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ugarte-Gil</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guio</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>NAT2 and CYP2E1 polymorphisms and antituberculosis drug-induced hepatotoxicity in Peruvian patients.</article-title>
            <source>Mol Genet Genomic Med</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>10</volume>
            <issue>8</issue>
            <fpage>e1987</fpage>
            <pub-id pub-id-type="pmid">35751408</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee Loy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chamarthi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Koratala</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>An uncommon cause of loss of vision in a dialysis patient with lupus.</article-title>
            <source>Clin Case Rep</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>244</fpage>
            <page-range>244-245</page-range>
            <pub-id pub-id-type="pmid">30656056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Si</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Ethambutol and isoniazid induced severe neurotoxicity in a patient undergoing continuous ambulatory peritoneal dialysis.</article-title>
            <source>BMJ Case Rep</source>
            <year>2018</year>
            <month>May</month>
            <day>18</day>
            <volume>2018</volume>
            <pub-id pub-id-type="pmid">29776936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Noguera-Pons</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Borr&#x000e1;s-Blasco</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Romero-Crespo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ant&#x000f3;n-Torres</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Navarro-Ruiz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Ferrandez</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Optic neuritis with concurrent etanercept and isoniazid therapy.</article-title>
            <source>Ann Pharmacother</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>39</volume>
            <issue>12</issue>
            <fpage>2131</fpage>
            <page-range>2131-5</page-range>
            <pub-id pub-id-type="pmid">16264061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gourishankar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Debroy</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>KC</given-names>
              </name>
            </person-group>
            <article-title>Isoniazid hepatotoxicity with clinical and histopathology correlate.</article-title>
            <source>Ann Clin Lab Sci</source>
            <year>2014</year>
            <season>Winter</season>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>87</fpage>
            <page-range>87-90</page-range>
            <pub-id pub-id-type="pmid">24695480</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Philipose</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Suchman</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Aronsky</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>TP</given-names>
              </name>
            </person-group>
            <article-title>A Case of Acute Liver Failure in a Patient on Isoniazid Prophylaxis for Latent Tuberculosis.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>e22452</fpage>
            <pub-id pub-id-type="pmid">35345710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peloquin</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Namdar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dodge</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Nix</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids.</article-title>
            <source>Int J Tuberc Lung Dis</source>
            <year>1999</year>
            <month>Aug</month>
            <volume>3</volume>
            <issue>8</issue>
            <fpage>703</fpage>
            <page-range>703-10</page-range>
            <pub-id pub-id-type="pmid">10460103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alsultan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peloquin</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic drug monitoring in the treatment of tuberculosis: an update.</article-title>
            <source>Drugs</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>74</volume>
            <issue>8</issue>
            <fpage>839</fpage>
            <page-range>839-54</page-range>
            <pub-id pub-id-type="pmid">24846578</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Babalik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Babalik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mannix</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Menzies</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic drug monitoring in the treatment of active tuberculosis.</article-title>
            <source>Can Respir J</source>
            <year>2011</year>
            <season>Jul-Aug</season>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>225</fpage>
            <page-range>225-9</page-range>
            <pub-id pub-id-type="pmid">22059181</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lheureux</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Penaloza</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gris</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pyridoxine in clinical toxicology: a review.</article-title>
            <source>Eur J Emerg Med</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>78</fpage>
            <page-range>78-85</page-range>
            <pub-id pub-id-type="pmid">15756083</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siskind</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Thienemann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kirlin</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Isoniazid-induced neurotoxicity in chronic dialysis patients: report of three cases and a review of the literature.</article-title>
            <source>Nephron</source>
            <year>1993</year>
            <volume>64</volume>
            <issue>2</issue>
            <fpage>303</fpage>
            <page-range>303-6</page-range>
            <pub-id pub-id-type="pmid">8321366</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kocabay</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Erelel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tutkun</surname>
                <given-names>IT</given-names>
              </name>
              <name>
                <surname>Ecder</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Optic neuritis and bitemporal hemianopsia associated with isoniazid treatment in end-stage renal failure.</article-title>
            <source>Int J Tuberc Lung Dis</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>12</issue>
            <fpage>1418</fpage>
            <page-range>1418-9</page-range>
            <pub-id pub-id-type="pmid">17171829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uzman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Uluda&#x0011f; Yanaral</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Topta&#x0015f;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ko&#x000e7;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ta&#x0015f;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bican</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Acute isoniazid intoxication: an uncommon cause of convulsion, coma and acidosis.</article-title>
            <source>Tuberk Toraks</source>
            <year>2013</year>
            <volume>61</volume>
            <issue>1</issue>
            <fpage>50</fpage>
            <page-range>50-3</page-range>
            <pub-id pub-id-type="pmid">23581267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Orlowski</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Paganini</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Pippenger</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Treatment of a potentially lethal dose isoniazid ingestion.</article-title>
            <source>Ann Emerg Med</source>
            <year>1988</year>
            <month>Jan</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>73</fpage>
            <page-range>73-6</page-range>
            <pub-id pub-id-type="pmid">3337420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <collab>Centers for Disease Control and Prevention (CDC)</collab>
            <article-title>Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2010</year>
            <month>Mar</month>
            <day>05</day>
            <volume>59</volume>
            <issue>8</issue>
            <fpage>224</fpage>
            <page-range>224-9</page-range>
            <pub-id pub-id-type="pmid">20203555</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de' Clari</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>The paradoxical anticonvulsive and awakening effect of high-dose pyridoxine treatment for isoniazid intoxication.</article-title>
            <source>Arch Intern Med</source>
            <year>1992</year>
            <month>Nov</month>
            <volume>152</volume>
            <issue>11</issue>
            <fpage>2346</fpage>
            <page-range>2346-7</page-range>
            <pub-id pub-id-type="pmid">1290558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blanchard</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>McAlpine</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Hurt</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Isoniazid overdose in the Cambodian population of Olmsted County, Minnesota.</article-title>
            <source>JAMA</source>
            <year>1986</year>
            <month>Dec</month>
            <day>12</day>
            <volume>256</volume>
            <issue>22</issue>
            <fpage>3131</fpage>
            <page-range>3131-3</page-range>
            <pub-id pub-id-type="pmid">3783848</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mowry</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Shepherd</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Lavergne</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gosselin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nolin</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Vijayan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kielstein</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Ghannoum</surname>
                <given-names>M</given-names>
              </name>
              <collab>Extracorporeal Treatments in Poisoning workgroup</collab>
            </person-group>
            <article-title>Extracorporeal treatments for isoniazid poisoning: Systematic review and recommendations from the EXTRIP workgroup.</article-title>
            <source>Pharmacotherapy</source>
            <year>2021</year>
            <month>May</month>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>463</fpage>
            <page-range>463-478</page-range>
            <pub-id pub-id-type="pmid">33660266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Durand</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jebrak</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pessayre</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fournier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bernuau</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.</article-title>
            <source>Drug Saf</source>
            <year>1996</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>394</fpage>
            <page-range>394-405</page-range>
            <pub-id pub-id-type="pmid">8968694</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farrell</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Keeffe</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Man</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Imperial</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Esquivel</surname>
                <given-names>CO</given-names>
              </name>
            </person-group>
            <article-title>Treatment of hepatic failure secondary to isoniazid hepatitis with liver transplantation.</article-title>
            <source>Dig Dis Sci</source>
            <year>1994</year>
            <month>Oct</month>
            <volume>39</volume>
            <issue>10</issue>
            <fpage>2255</fpage>
            <page-range>2255-9</page-range>
            <pub-id pub-id-type="pmid">7924752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalsi</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Waring</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Dargan</surname>
                <given-names>PI</given-names>
              </name>
            </person-group>
            <article-title>Does cytochrome P450 liver isoenzyme induction increase the risk of liver toxicity after paracetamol overdose?</article-title>
            <source>Open Access Emerg Med</source>
            <year>2011</year>
            <volume>3</volume>
            <fpage>69</fpage>
            <page-range>69-76</page-range>
            <pub-id pub-id-type="pmid">27147854</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Self</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Chrisman</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Baciewicz</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bronze</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Isoniazid drug and food interactions.</article-title>
            <source>Am J Med Sci</source>
            <year>1999</year>
            <month>May</month>
            <volume>317</volume>
            <issue>5</issue>
            <fpage>304</fpage>
            <page-range>304-11</page-range>
            <pub-id pub-id-type="pmid">10334118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shimokawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yoda</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kondo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yamamura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Takiguchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Umehara</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Inhibitory Potential of Twenty Five Anti-tuberculosis Drugs on CYP Activities in Human Liver Microsomes.</article-title>
            <source>Biol Pharm Bull</source>
            <year>2015</year>
            <volume>38</volume>
            <issue>9</issue>
            <fpage>1425</fpage>
            <page-range>1425-9</page-range>
            <pub-id pub-id-type="pmid">26094899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lejonc</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Schaeffer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brochard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Portos</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>[Paroxystic hypertension after ingestion of gruyere cheese during isoniazide treatment: a report on two cases (author's transl)].</article-title>
            <source>Ann Med Interne (Paris)</source>
            <year>1980</year>
            <volume>131</volume>
            <issue>6</issue>
            <fpage>346</fpage>
            <page-range>346-8</page-range>
            <pub-id pub-id-type="pmid">7469238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>XG</given-names>
              </name>
              <name>
                <surname>Mou</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Design, Synthesis, and Evaluation of Monoamine Oxidase A Inhibitors&#x0207b;Indocyanine Dyes Conjugates as Targeted Antitumor Agents.</article-title>
            <source>Molecules</source>
            <year>2019</year>
            <month>Apr</month>
            <day>10</day>
            <volume>24</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">30974737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ishikawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Okayama</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>An outbreak of histamine poisoning after ingestion of the ground saury paste in eight patients taking isoniazid in tuberculous ward.</article-title>
            <source>Intern Med</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>44</volume>
            <issue>11</issue>
            <fpage>1133</fpage>
            <page-range>1133-6</page-range>
            <pub-id pub-id-type="pmid">16357449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glatstein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carbell</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Scolnik</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rimon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Banerji</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hoyte</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Pyridoxine for the treatment of isoniazid-induced seizures in intentional ingestions: The experience of a national poison center.</article-title>
            <source>Am J Emerg Med</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>36</volume>
            <issue>10</issue>
            <fpage>1775</fpage>
            <page-range>1775-1778</page-range>
            <pub-id pub-id-type="pmid">29397257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arsalan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sabzwari</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Isoniazid induced motor-dominant neuropathy.</article-title>
            <source>J Pak Med Assoc</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>65</volume>
            <issue>10</issue>
            <fpage>1131</fpage>
            <page-range>1131-3</page-range>
            <pub-id pub-id-type="pmid">26440850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yadav</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chacham</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pyridoxine in isoniazid-induced psychosis.</article-title>
            <source>Sudan J Paediatr</source>
            <year>2022</year>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>190</fpage>
            <page-range>190-192</page-range>
            <pub-id pub-id-type="pmid">36875946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freiman</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Muyindike</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Horsburgh</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Ellner</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Linas</surname>
                <given-names>BP</given-names>
              </name>
            </person-group>
            <article-title>Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2018</year>
            <month>Apr</month>
            <day>01</day>
            <volume>77</volume>
            <issue>4</issue>
            <fpage>405</fpage>
            <page-range>405-412</page-range>
            <pub-id pub-id-type="pmid">29239900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23787.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Denholm</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>McBryde</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Eisen</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Penington</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Street</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects of isoniazid preventative therapy for latent tuberculosis infection: a prospective cohort study.</article-title>
            <source>Drug Healthc Patient Saf</source>
            <year>2014</year>
            <volume>6</volume>
            <fpage>145</fpage>
            <page-range>145-9</page-range>
            <pub-id pub-id-type="pmid">25364275</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
